Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients
Abstract Background Vascular endothelial growth factor C (VEGFC), an activator of lymphangiogenesis, is newly identified as an immunomodulator which can regulate the immune system so that tumor cells more easily escape immune surveillance. Evidence has shown programmed cell death‐ligand 1 (PD‐L1) ca...
Saved in:
| Main Authors: | Tingting Qin, Junling Xia, Shaochuan Liu, Jing Wang, Hailin Liu, Yan Zhang, Yanan Jia, Kai Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-05-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis
by: Zhiyong Wan, et al.
Published: (2025-01-01) -
A Population Survival Kinetics Assessment of Extensive Small Cell Lung Cancer and Rationale for Maintenance Therapy
by: David J. Stewart, et al.
Published: (2025-04-01) -
Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials
by: Eva Rahman Kabir, et al.
Published: (2024-10-01) -
Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review
by: Elyar Mahboubi, et al.
Published: (2025-05-01) -
The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
by: Made Agus Mahendra Inggas, et al.
Published: (2025-03-01)